Lentiviral Vector Manufacturing and Distribution

Gene and cell therapy medicines, in particular those delivered via lentiviruses, are poised to be the future of disease treatment. The complex production process required to generate a single lentiviral vector application, however, poses several challenges to researchers and businesses aiming to further their research and commercially distribute these life-saving cures.

The Center for Breakthrough Medicines offers a smooth and safe tech transfer process for researchers looking to take their work to the next level of development and scale-up. Our current good manufacturing practices (cGMP) compliant facility allows you to move ongoing manufacturing and testing without compromising the integrity of your research. If your team is looking to capitalize on their lentiviral vector discoveries, you’ll find the resources needed to move quickly and confidently through the processes along the path from production to distribution at Center for Breakthrough Medicines.

We have the infrastructure and business services needed to rapidly produce market-ready breakthroughs in cell and gene therapy, including 1 million square feet of office and lab space, plus $1B of infrastructure.

What are lentiviral vectors?
Lentiviruses are a genus of the Retroviridae family. Examples of lentiviruses include HIV, SIV, and FIV.

Researchers are currently developing novel drugs which aim to block specific gene products to treat various diseases. Lentiviruses can also be used to introduce new genes into human cells.

Lentiviruses are being used in clinical trials aiming to treat and cure various diseases, including:

• Hemophilia

• Diabetes

• Prostate cancer

• Cystic fibrosis

• Chronic granulomatous disease

• Vascular diseases

• Rheumatoid arthritis

Why lentiviruses?
Using lentiviruses to create lentiviral vectors is considered one of the most efficient methods of gene delivery. These vectors offer several benefits over other viral vectors.

• Lentiviruses can deliver a significant amount of genetic information into the DNA of the host cell.

• They can be delivered directly into the body without in vitro manipulations of the patient’s cells.

• They have the unique ability to infect dividing and non-dividing cells. This means there’s a wider range of potential uses for lentiviral vectors.

• Lentiviruses can integrate their genome into the host genome. Any genetic changes may be inherited by the host’s descendants

How are lentiviral vectors manufactured?
The most common way to produce lentiviral vectors is in a transient transfection system. These systems require a lentiviral transfer vector plasmid, packaging plasmids, and a plasmid with an envelope gene of a different virus

After an incubation period, the virus is stored or centrifuged to concentrate. For smaller-scale production and R&D purposes, this can be done in Petri dishes, T-flasks, multitray systems (Cell Factories or Cell Stacks), or HYPERFlasks.

The Center for Breakthrough Medicines is a cGMP-compliant facility with the ability for both scale-up in suspension bioreactors or scale-out with modulate suites, which will allow for efficient large-scale production of safe and effective lentiviral vectors.

Learn more about Center for Breakthrough Medicines viral vector capabilities: https://breakthroughmedicines.com/viral-vector-manufacturing/